McClanahan D, Wong A, Kezic S, et al. - In this single-centre, investigator-blinded, randomized controlled trial, researchers ascertained if the daily full-body application of an emollient with ceramide and amino acids (study emollient) can lessen the cumulative atopic dermatitis (AD) incidence compared with standard skin care at 1 year of age, as well as assessed the study emollient's impact on skin barrier function, natural moisturizing factor and the microbiome using non-invasive biophysical and biochemical techniques. Data reported that AD was diagnosed in 13.2% vs 25.0% at 12 months and 19.4% vs 31.0% at 2 years in the intervention vs control groups, respectively. No significant differences were found between groups in skin barrier or microbiome evaluations. While no serious adverse events occurred, the intervention vs control arms contained more cases of reported contact dermatitis, 9.3% vs 4.3%, respectively. However, these events were not related to the study emollient and most mild in severity. The observed trends suggest that daily study emollient therapy has a protective effect compared with control.